{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"13.8","upperLimit":"23.1","value":"18.5"},{"groupId":"OG001","lowerLimit":"18.2","upperLimit":"28.6","value":"23.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"271"},{"groupId":"OG001","value":"256"}],"units":"Participants"}],"description":"Overall objective tumor response was defined as either a partial response (PR) or complete response (CR) according to the RECIST 1.1 criteria, as assessed by the investigator. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must had reduction in short axis to \\<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cabazitaxel 20 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG000","title":"Cabazitaxel 20 mg/m^2"},{"description":"Cabazitaxel 25 mg/m\\^2 IV infusion over 1 hour on Day 1 of each 21-day cycle in combination with Prednisone (or Prednisolone) 10 mg orally daily until DP, unacceptable toxicity, participant's refusal of further study treatment or for a maximum of 10 cycles.","id":"OG001","title":"Cabazitaxel 25 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Analysis was performed on ITT population. Number of participants analyzed= participants evaluable for tumor response with measurable disease at baseline and at least one valid post-baseline value.","reportingStatus":"POSTED","timeFrame":"From baseline up to DP or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 48 months)","title":"Percentage of Participants With Overall Objective Tumor Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}